Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics

摘要

a Treatment (colored boxes) and biopsy (red stars) timeline, in months, following disease recurrence in the metastatic setting. b Timeline of blood biomarker levels (U/ml, solid lines) and lesion sizes (in millimeters) for four selected hepatic lesions (hatched lines). Study biopsy #1 (Bx#1) = Liver 3 segment 2 (L3 seg2); Study biopsy #2 (Bx#2) = Liver 4 segment 5/6 (L4 seg5/6).